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ABSTRACT
The Philadelphia chromosome (Ph)-negative myeloproliferative disorders (MPDs) include essential throm-
bocythemia (ET), idiopathic myelofibrosis (IMF), and polycythemia vera (PV). All of these disorders are clonal
hematologic malignancies originating at the level of the pluripotent hematopoietic stem cell. Recently,
activating mutations of the intracellular cytokine-signaling molecule JAK2 have been identified in > 90% of
patients with PV and in 50% of those with IMF and ET. In addition, a mutation of the thrombopoietin
receptor, MPLW515L, has been documented in some patients with IMF. Both mutations activate JAK-STAT
signaling pathways and likely play a role in disease progression. Both ET and PV are associated with prolonged
clinical courses associated with frequent thrombotic and hemorrhagic events, and progression to myelofibrosis
and acute leukemia. IMF has a much poorer prognosis and is associated with cytopenias, splenomegaly,
extramedullary hematopoiesis, and bone marrow fibrosis. Stratification of risk for the development of com-
plications from Ph-negative MPDs has guided the identification of appropriate therapies for this population.
Intermediate/high-risk IMF or myelofibrosis after ET or PV is associated with a sufficiently poor prognosis to
justify the use of allogeneic stem cell transplantation, which is capable of curing such patients. Reduced-
intensity conditioning in preparation for allogeneic stem cell transplantation has permitted older patients with
IMF to undergo transplantation with increasing success.
© 2007 American Society for Blood and Marrow Transplantation
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The chronic myeloproliferative disorders (MPDs)
nclude chronic myeloid leukemia (CML), thrombo-
ythemia (ET), idiopathic myeloﬁbrosis (IMF), and
olycythemia vera (PV). Dameshek [1], in 1951, ﬁrst
ecognized the similarities between these disorders
nd documented that each was capable of terminating
n either a bone marrow failure disorder, characterized
y bone marrow ﬁbrosis, or a blastic phase resembling
cute leukemia. Subsequently, each of these disorders
as been shown to be a clonal hematologic malignancy
riginating at the pluripotent hematopoietic stem cell
HSC) level. Progress in the diagnosis and treatment
f CML has been facilitated by the discovery of the f
4hiladelphia chromosome (Ph), a balanced transloca-
ion that fuses the BCR gene on chromosome 22 to the
BL gene on chromosome 9. The resulting BCR-ABL
usion gene encodes a cytoplasmic protein with con-
titutive tyrosine kinase activity. This fusion gene
roduct has served as a target for drug development
nd has resulted in the discovery of several small
olecule inhibitors of BCR-ABL, including imatinib,
asatinib, and nilotinib, which has revolutionized the
reatment of patients with CML. Unfortunately,
rogress in our understanding of PV, ET, and IMF
as been considerably slower. The increased sensitiv-
ty of hematopoietic progenitor cells from patients
ith PV, ET, and IMF to a wide variety of growth
actors has led to attempts by numerous investigators
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Philadelphia Chromosome–Negative Myeloproliferative Disorders 65o deﬁne molecular abnormalities within common in-
racellular signaling pathways that might underlie the
iogenesis of Ph-negative MPDs. The recent identi-
cation of activating mutations of the intracellular
ytokine-signaling molecule, Janus kinase 2 (JAK2),
nd the thrombopoetin receptor, MPL, has resulted
rom such efforts and has led to the generation of
opious new data on the pathobiology of PV, ET, and
MF [2,3]. The discovery of these mutations has also
esulted in a ﬂurry of activity directed toward the
evelopment of small molecule inhibitors with the
ope of creating speciﬁc nontoxic agents for treating
h-negative MPDs.
OLECULAR BIOLOGY OF THE
HILADELPHIA CHROMOSOME–NEGATIVE
YELOPROLIFERATIVE DISORDERS
PV, the most common MPD, originates from a
ingle hematopoietic stem cell precursor. The princi-
al molecular mechanism by which the abnormal PV
lone develops and propagates is based on the ability
f PV progenitor cells to form erythroid colonies in
he absence of exogenous erythropoietin (Epo) [4]. In
ddition, the erythroid clone is hypersensitive to stim-
lating cytokines, such as insulin-like growth factor-1
5] or, to a lesser degree, interleukin-3 and granu-
ocyte macrophage colony-stimulating factor [6],
uggesting that this propagation occurs because of
ranscriptional dysregulation affecting a number of
roteins involved in cytokine receptor signaling [7].
any pathophysiologic mechanisms of the molecular
echanisms of PV: the absence of an alternative prod-
ct of the Epo receptor (EpoR) gene, which inhibits
poR-controlled erythropoiesis [8]; overexpression of
he PRV-1 gene, which belongs to the urokinase-type
lasminogen activator receptor superfamily [9]; dereg-
lation of Bcl-x, which is an inhibitor of apoptosis
10]; and increases of p16 protein [11] and tyrosine
hosphatase activity in red cell precursors [12].
Genome-wide scanning comparison of PV clonal
nd polyclonal cells from same individuals revealed a
oss of heterozygosity (LOH) in chromosome 9p,
ound in approximately 30% of PV patients. This
OH is not a result of a chromosomal deletion, but
ather results from a duplication of 1 parental allele
nd loss of the corresponding partner’s allele, that is,
niparenteral disomy. Of note, the 9p region codes for
he p16 and JAK2 tyrosine kinase gene [13]. The JAK
amily of protein tyrosine kinases is involved in cyto-
ine receptor signaling, transmits the activating signal
n the Epo–EpoR signaling pathway, and also is a
equired subunit for surface expression of cytokine
eceptors [14], including EpoR [15]. Ugo et al. have
hown that inhibition of JAK2 abrogated Epo inde-
endence of erythroid progenitors [16]; this observa- cion was followed by a description of the principal
efect of the molecular basis of Ph-negative MPD,
hat is, a loss-of-function somatic mutation of an au-
oinhibitory JAK2 domain resulting from a valine-to-
henylalanine mutation at amino acid JAK2V617F
2]. JAK2V617F leads to ongoing phosphorylation
ctivity, which then can bind to a receptor and pro-
ote STAT recruitment and increased expression of
RV-1 [17]. This recruitment occurs in the absence of
po [18,19]. This helps explain the known observed
henomenon of in vitro cytokine hypersensitivity [14].
urthermore, in a mouse bone marrow transplant
odel, murine marrow cells transduced with the JAK2
utant allele led to a clinical phenotype consistent
ith PV, which included erythrocytosis, extramedul-
ary hematopoiesis, and marrow ﬁbrosis [2]. This sem-
nal work was rapidly conﬁrmed by multiple groups,
ll of which demonstrated that 90% of patients with
V and lower but still signiﬁcant proportions of pa-
ients with ET and IMF carry the JAK2V617F muta-
ion [20]. However, contradictory data exist as to
hether or not this mutation is classically dominant
14]. A study of 193 patients without 9p LOH found
hat 66 of 193 were heterozygous and 127 did not have
he JAK2V617F mutation [19], ﬁndings similar to
ther reports, which also conﬁrmed that approxi-
ately 30% of PV patients were homozygous for
AK2V617F [18,21-24].
The JAK2V617F mutation also appears to play a
ole in IMF and ET. Approximately 50%–70% of
T patients and  50% of IMF patients have the
AK2V617F somatic mutation [3,25]. Presumably,
his JAK2 mutation leads to a proliferation of clonal
SCs in these disorders through similar mechanisms
s found in PV; however, the exact processes are not
lear. Also, the fact that many of these patients do not
ave the JAK2V617F mutation raises other signiﬁcant
uestions regarding etiology, speciﬁcally, what other
utations may exist that lead to these phenotypes in
atients in whom the JAK2V617F mutation is not
resent. In this context, another important somatic
utation was identiﬁed in the transmembrane domain
f the thrombopoietin receptor (cMPL) in 9% (4/45)
atients with JAK2V617F-negative IMF [3,26]. The
urine model of this mutation, but not the wild-type
PL, led to a fully penetrant MPD characterized by
arked thrombocytosis, marked splenomegaly, and
ncreased reticulin ﬁbrosis. Interestingly, and signiﬁ-
antly, a small-molecule JAK inhibitor, in vitro, inhib-
ted MPLW515L-mediated proliferation and JAK-
TAT signaling [3]. This recent work demonstrated
hat this mutation, MPLW515L, also activates the
AK-STAT signaling pathway, and that the likely
resence of multiple other somatic and/or germ-line
utations besides JAK2V617F and MPLW515L will
ctivate this signaling cascade and may account for the
ases of JAK2V617F-negative IMF and ET. However,
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R. Hoffman et al.66hether the JAK2V617F mutation is the PV disease
nitiating mutation is not clear; some PV JAK2V617F-
egative patients have monoclonal hematopoiesis and
po-independent erythropoiesis, and in some individ-
al PV families there are PV subjects with and without
he JAK2V617F mutation.
To contribute to resolution of this issue, we have
eveloped a novel approach to primer design for
eal-time quantitative allele-speciﬁc polymerase
hain reaction for precise analysis of wild and mutant
AK2V617F. A proportion of 0, 50%, or 100%
AK2V617F allele was expected from each individual
FU-E colony, which indeed was observed. However,
hen we tested granulocytes from PV females, in
hom the granulocytes were found to be clonal by the
-chromosome transcriptional-based clonality assay,
e found 3 females with  50% (27.5%  11%) and
females with  50% (75%  10.5%) mutant JAK2
llele frequencies. These results indicate the presence
f a heterogeneous population of cells with differing
enotypes regarding the JAK2V617F allele. This con-
lusion is further supported by the fact that although
ost PV BFU-E colonies are homozygous for the
AK2V617F mutation, some are heterozygous, and
are colonies are of the wild-type JAK2 genotype.
hese data indicate that JAK2V617F is not the PV-
nitiating mutation. Finally, although JAK2 clearly
lays a signiﬁcant role in Ph-negative MPDs, its pres-
nce is not entirely speciﬁc for MPDs. This mutation
as been found in myelodysplastic syndromes, chronic
yelomonocytic leukemia, CML, acute myeloid leu-
emia (AML), and other hematologic malignancies
22,23]. Much work remains on identifying the initi-
ting genetic events in the pathogenesis of these dis-
rders. Meanwhile, these molecular aberrations will
opefully provide speciﬁc targets for therapeutic
nterventions.
LINICAL OUTCOMES AND TREATMENT OF
YELOPROLIFERATIVE DISORDERS
The Ph-negative MPDs are clonal hematopoietic
tem cell disorders characterized by proliferation in
he bone marrow of 1 or more of the myeloid (gran-
locytic, erythroid, and megakaryocytic) lineages. In
V and ET, this proliferation is associated with rela-
ively normal effective blood cell production, resulting
n increased numbers of granulocytes, red blood cells,
nd/or platelets in the peripheral blood. Advanced
orms of IMF, in contrast to ET and PV, are charac-
erized by ineffective hematopoiesis, leading to the
evelopment of cytopenias. Megakaryocytic hyper-
lasia is the pathological hallmark of the bone mar-
ow in each Ph-negative MPD. In Ph-negative
PDs, splenomegaly and hepatomegaly are common,
aused by sequestration of excess blood cells, as well as
xtramedullary hematopoiesis. lDespite their insidious clinical onset, PV and ET
ave the potential to undergo clonal evolution and a
tepwise progression that terminates in 1 of 3 out-
omes: bone marrow failure syndrome that resembles
MF, a disorder characterized by ineffective hemato-
oiesis similar to a myelodysplastic disorder, or trans-
ormation to an acute blastic phase that is refractory to
nduction chemotherapy. Both ET and PV are asso-
iated with prolonged clinical courses involving fre-
uent thrombotic episodes and hemorrhagic events.
ith appropriate treatment, patients with these dis-
rders often survive for more than 15 years. In fact, 1
etrospective series of 322 patients with ET found a
edian survival of 18.9 years [27]. In another series of
32 patients with ET, the probability of developing
yeloﬁbrosis was 9.7%, with a latency period of 8
ears, and the latency period for developing AML was
0 years [28].
The primary clinical manifestations of PV and ET
re the direct consequence of the excessive prolifera-
ion of the cellular elements of the various lineages
nvolved in the neoplastic process. Due to the wide-
pread use of laboratory screening tests during routine
atient examinations, increasing numbers of persons
re being diagnosed with PV and ET before the ap-
earance of symptoms. Thrombosis is the most com-
on presenting event. In both ET and PV, arterial
hrombotic events account for the overwhelming
umber of such events, with venous thrombotic events
epresenting the remainder. Ischemic stroke, myocar-
ial infarction, and transient ischemic attacks are the
ost common arterial thrombotic events. It is not
nusual for patients with PV to develop thromboses at
nusual anatomic sites; particular, thromboses are rel-
tively more frequent in the splenic, hepatic, portal,
nd mesenteric vessels, as well as in the cerebral si-
uses. A particularly serious thrombotic event associ-
ted with PV and ET is Budd-Chiari syndrome, which
esults from hepatic vein or inferior vena caval throm-
osis and obstruction. In this disorder, reduced portal
ein perfusion leads to portal vein thrombosis and
ypoxic damage of liver parenchymal cells, culminat-
ng in a cascade of events that results in cirrhosis of the
iver. In a signiﬁcant population of patients, serious
hrombotic events, such as Budd-Chiari syndrome,
ccur before the diagnosis of PV or ET and serve as a
orme fruste of the underlying MPD [29].
The World Health Organization has developed a
seful set of criteria for the diagnosis of the Ph-
egative MPD, which has been supplemented by
he use of molecular diagnostic tools to identify the
AK2V617F mutation [2,21,30]. Prospective data
rom the United Kingdom has demonstrated that
he presence or absence of JAK2V617F distin-
uishes 2 biologically distinct subsets of ET, with the
AK2V617F-positive subpopulation exhibiting many
aboratory and clinical similarities to PV [31]. These
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Philadelphia Chromosome–Negative Myeloproliferative Disorders 67ata suggest that JAK2V617F PV and ET represent a
iological continuum, with the degree of erythrocyto-
is determined by physiological or genetic modiﬁers.
he recent identiﬁcation of distinct cytogenetic ab-
ormalities with JAK2V617F-positive (20q- and tri-
omy 9) and JAK2V617F-negative (13q) cases of
PD suggest that these 2 subpopulations might rep-
esent distinct types of MPD [32].
It had previously been assumed that the AML
eveloping in PV patients represents the clonal evo-
ution of the original malignant clone. Recently,
ampbell et al. [32] challenged this concept by show-
ng that in 3 of 4 patients with a JAK2V617F MPD
hat transformed to AML, the leukemic cells were
AK2V617F-negative. These authors conjectured that
he AML originated either in a residual normal stem
ell population or in a cell belonging to an initial
re-JAK2V617F phase of the disease resulting from
n as-yet unidentiﬁed mutation [32].
The core treatment regimen for PV is phlebotomy
nd low-dose aspirin therapy, with the goal of nor-
alizing hematocrit and reducing platelet function
33]. This simple treatment plan is directed toward
educing the risk of developing additional thrombo-
es. The use of other therapeutic modalities, such as
ydroxyurea, interferon, or anagrelide, is reserved for
atients over age 65 years or those with a previous
istory of thrombosis. This risk-stratiﬁed approach
as been used almost universally to target those indi-
iduals at the greatest risk for developing additional
hrombotic events [33]. These therapies have not been
hown to delay progression to myeloﬁbrosis, myelo-
ysplasia, or acute leukemia. The use of a pegylated
orm of alpha-interferon has recently been reported to
educe the burden of JAK2V617F and restore poly-
lonal hematopoiesis in patients with PV; this is the
rst evidence of a therapeutic strategy capable of elim-
nating the malignant PV clone [34]. The use of alky-
ating agents (eg, chlorambucil) and radioactive phos-
horous in PV patients has been shown to increase the
isk of developing acute leukemia. Hydroxyurea is still
idely used in high-risk ET and PV patients and
emains an effective agent, associated with a limited
isk of transformation to acute leukemia [35]. Al-
hough normalization of the hematocrit in PV pa-
ients reduces the risk of thrombosis, the normaliza-
ion of platelet numbers has not been demonstrated to
urther reduce this risk.
Treatment of patients with ET is less well estab-
ished. Patients with ET who are under age 65 years or
ho have not experienced a thrombotic event are
onsidered low risk and are treated with low-dose
spirin or simply observed [36]. Patients with high-
isk disease usually receive platelet reduction therapy
ith anagrelide, hydroxyurea, or interferon. Reduc-
ion of platelet numbers with hydroxyurea has been
hown to reduce the risk of developing additional shrombotic episodes in this high-risk group of ET
atients. Ironically, patients with the highest platelet
ounts ( 1500  109/L) are at greater risk of bleed-
ng. A recent large randomized study of high-risk ET
atients found that hydroxyurea and aspirin therapy
as superior to anagrelide therapy in treating pa-
ients with ET by reducing the risk of developing
rterial thromboses and transforming to myeloﬁ-
rosis while minimizing the risk of developing hem-
rrhagic events [36].
Clearly, the Ph-negative MPD with the most se-
ious prognosis is IMF, which is associated with a
edian survival of approximately 5 years. IMF is char-
cterized by cytopenias, megakaryocytic hyperplasia,
plenomegaly, extramedullary hematopoiesis, a leuko-
rythroblastic blood picture, “teardrop” red cells,
one marrow ﬁbrosis, constitutive mobilization of
one marrow CD34 cells, and increased bone mar-
ow microvessel density. The bone marrow ﬁbrosis
esults from the release of various cytokines (ie, trans-
orming growth factor-, ﬁbroblast growth factor, and
latelet-derived growth factor) by the cellular progeny
f IMF stem cells within the bone marrow microen-
ironment. Although the bone marrow histopathology
s distorted by ﬁbrosis, once the number of malignant
ells is reduced by chemotherapy in preparation for
llogeneic stem cell transplantation, normal homing
nd engraftment of normal stem cells apparently oc-
ur. The kinetics of engraftment suggest that the bone
arrow niche is not irreversibly altered by the bone
arrow ﬁbrosis accompanying IMF. The constitutive
obilization of hematopoietic stem and progenitor
ells and likely endothelial progenitor cells in IMF
atients results in the seeding of extramedullary sites
ith foci of hematopoietic cells, leading to establish-
ent of extramedullary hematopoiesis [37,38]. This
onstitutive mobilization is a consequence of the re-
ease of proteases (MMP-9 and neutrophil elastase),
hich reduce retention within the bone marrow
iches of hematopoietic stem cells and progenitor
ells [39].
The most common symptoms of IMF result from
evere anemia. With enlargement of the spleen, ab-
ominal discomfort may occur due to distention of the
plenic capsule, splenic infarcts, or mechanical pres-
ure of the enlarged spleen on other intra-abdominal
rgans. Bleeding due to thrombocytopenia or qualita-
ive abnormalities of platelet function or thrombotic
pisodes may punctuate the clinical course of patients
ith IMF. Extramedullary hematopoiesis in the gas-
rointestinal, central nervous, pulmonary, and genito-
rinary systems may produce symptoms due to enlarg-
ng masses or impaired organ function.
Between 20% and 25% of patients are believed
o present with a preﬁbrotic form of IMF that
anifests as mild anemia, thrombocytosis, or
plenomegaly. Morphological abnormalities of bone
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R. Hoffman et al.68arrow megakaryocytes distinguish these patients
rom those with ET. Patients with the preﬁbrotic
orm of the disease are frequently asymptomatic, and
heir outcome is extremely favorable. Only a fraction
o on to develop classical symptomatic forms of IMF,
nd many remain stable for well over a decade.
Patients with more advanced forms of IMF fre-
uently require therapeutic intervention due to cyto-
enias, splenomegaly, infectious complications, or
hrombosis. Splenectomy has been used to correct the
onsequences of massive splenomegaly. Transfusion
herapy is the core strategy for treating both anemia
nd thrombocytopenia. A number of agents, including
anazol, erythropoietin, thalidomide, lenalidomide,
ydroxyurea, anagrelide, melphalan, and busulfan,
ave been used to correct the cytopenias, halt the
rogression of splenomegaly, or reduce the size of a
xtramedullary hematopoiesis site. To date, drug ther-
py has not been shown to alter the natural history of
MF; however, drug therapy is frequently effective in
alliating symptoms or reducing the requirements for
ransfusion therapy.
Allogeneic stem cell transplantation is the only
herapeutic modality with the potential to cure IMF
40]. Selecting appropriate candidates for transplanta-
ion with sufﬁciently poor prognoses to justify the risk
ssociated with this approach is challenging. Clinical
nd biological parameters characteristic of IMF pa-
ients at diagnosis have been used to identify sub-
roups of patients with different outcomes. The most
idely used risk assessment tool for assessing the
rognosis of IMF patients, the Lille scoring system, is
rovided in Table 1. This system, created by Dupriez
t al. [41], has proven useful in selecting intermediate
nd higher-risk patients as candidates for allogeneic
tem cell transplantation. Patients with a Lille score of
or those with a preﬁbrotic form of IMF should not
e considered for transplantation due to their favor-
ble prognosis. Recently, Dingli et al. [42] attempted
o improve on the Lille scoring system by analyzing
he characteristics of 160 patients with IMF who were
ll under age 60 and had a median overall survival of
8 months. These authors found that a platelet count
f 100  109/L was associated with adverse outcome
n these patients. They created a complete blood
ount scoring system using 3 parameters (Hgb  10
/dL, WBC  4 or  30  109/L, and platelet count
able 1. Risk Assessment in Myeloﬁbrosis: Lille Scoring System, Based
n the Number of Adverse Prognostic Factors [41]: Hgb  10 g/dL,
BC  4,000/L or  30,000/L
No. of Factors Risk Group Cases (%)
Median Survival
(months)
0 Low 47 93
1 Intermediate 45 261
2 High 8 13100  109/L). Each event was given a score of 1.
atients with a score of 0 had a median survival of 155
onths, those with a score of 1 had a median survival
f 69 months, and those with a score of  2 had a
edian survival of 23.5 months [42].
Because Dingli et al. [42] studied a population of
ounger patients, whereas Dupriez et al. [41] analyzed
he outcomes of IMF patients over the full age range,
etermining which assessment tool is optimal is im-
ossible. Clearly, both tools are useful. Most investi-
ators have assumed that the Lille scoring system is
lso useful in assessing the progress of patients with
yeloﬁbrosis (MF) after ET and PV. Dingli et al. [42]
nalyzed 66 patients under age 60 with this form of
F and found a median survival of 90 months, which
s considerably more favorable than had been reported
reviously. After multivariate analysis, age  45 years
nd a hemoglobin level  10 g/dL were identiﬁed as
ndependent risk factors for survival [43]. Unfavor-
ble cytogenetic abnormalities (other than 13 q
nd 20 q) were shown to be the most useful means
f identifying patients with poor outcomes in MF after
T and PV; patients with such unfavorable cytoge-
etic abnormalities have a median survival of 12
onths, compared with 204 months for patients
ith favorable cytogenetics [44]. The relatively favor-
ble outcome of patients with MF after ET or PV
eported by Dingli et al. [42] is not consistent with
hese authors’ clinical impressions and might be due
o the histopathologic deﬁnition of MF that they used.
one marrow ﬁbrosis commonly accompanies ET and
V, and its presence is not a sufﬁcient basis for a
linical diagnosis of MF.
TEM CELL TRANSPLANTATION IN MYELOFIBROSIS
The poor prognosis of patients with IMF, or MF
econdary to PV or ET, with intermediate/high-risk
isease and the lack of curative therapies for IMF have
rompted studies exploring the effects of allogeneic
ematopoietic stem cell transplantation (HSCT) [44-
0]. These studies using myeloablative conditioning
egimens demonstrated for the ﬁrst time the possibil-
ty of curing some patients with IMF in the chronic
hase, but indicated that allogeneic HSCT is unlikely
o cure patients with more advanced phases of the
isease, characterized by increased circulating blasts.
graft-versus-IMF activity by donor cells was also
ocumented by the beneﬁcial effect of donor lympho-
yte infusions in a patient who experienced relapse
arly after transplantation [51]. However, an unac-
eptable transplantation-related mortality (TRM)
anging between 25% and 48% limited the likelihood
f success to only a small subset of IMF patients. In
articular, IMF patients over age 45 experienced only
4% survival, as opposed to 62% in younger patients
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Philadelphia Chromosome–Negative Myeloproliferative Disorders 69years after allogeneic HSCT [52]. Because the av-
rage age of IMF patients is over 60 years, allogeneic
SCT, albeit possibly curative, does not appear to
epresent a valid option for most IMF patients. Be-
ause of the toxicity of allogeneic HSCT, the use of
igh-dose chemotherapy followed by autologous
SCT was also explored in a small series of IMF
atients whose stem cells were harvested before the
onditioning regimen [53]. This approach resulted in
ome amelioration of the hematologic condition, but
as been largely abandoned.
The recent development of pretransplantation
onditioning regimens using reduced-intensity condi-
ioning (RIC), either nonmyeloablative or moderately
yeloablative, has revealed that elderly patients with
alignant hematologic disorders can receive alloge-
eic HSCT with limited toxicity and TRM [54]. De-
ine et al. [55] ﬁrst demonstrated that IMF patients
ith intermediate/high-risk disease could achieve and
aintain complete remission after allogeneic RIC-
SCT. These patients were conditioned with ﬂudara-
ine and melphalan and experienced no major toxicity
espite having a median age  50 years. A retrospec-
ive analysis of 21 IMF patients in chronic phase
 5% blasts in the peripheral blood) with intermediate/
igh-risk disease and median age of 53 years who
eceived an RIC before allotransplantation (mostly
ith peripheral blood stem cells [PBSCs]) showed a
RM of 10%, an overall survival (OS) of 86%, and an
vent-free survival (EFS) of 76% after a median fol-
ow-up of 2.7 years [40]. These data were conﬁrmed in
pilot prospective trial [56], in which 5 low-risk and
6 intermediate/high-risk IMF patients (median age,
3 years) were conditioned with ﬂudarabine, reduced-
ose busulfan (10 mg/kg po) and antithymocyte glob-
lin (ATG) and received an allogeneic PBSC trans-
lant from related or unrelated donors. After a median
ollow-up of 22 months, these authors reported a
rojected OS of 84% and EFS of 83%. Indeed, these
tudies suggest that the age ( 45 years) may no
onger be a limiting factor in the outcome of alloge-
eic HSCT if an RIC is provided (Table 2). However,
t remains to be determined which conditioning reg-
able 2. Results in Previous Major Studies Using Fully Myeloablative
No. of patients
Age
(median)
Interm
High
(Duprie
uardiola et al. [48,52] 55 42 7
aly et al. [49] 25 48 8
eeg et al. [50] 56 45 5
ondelli et al. [40] 21 54 10
roger et al. [56] 21** 53 7
Median follow-up.
Eight siblings and 13 unrelated donors.men would result in the greatest antitumor effect
hile causing the least toxicity. The use of a combi-
ation of ﬂudarabine and melphalan for conditioning
efore transplantation produced promising results in a
imited number of patients who not only achieved a
omplete hematologic remission [40,55], but also were
hown to improve and ﬁnally obtain a histological
emission and a progressive regression of marrow ﬁ-
rosis 12 months after transplantation [57]. Interest-
ngly, in a few patients with extensive splenomegaly,
his regimen resulted in a signiﬁcant reduction in size
f the spleen within 2-3 days (D Rondelli and R
offman, unpublished data). In addition, the combi-
ation of thiotepa and cyclophosphamide has proven
ffective [40]. Busulfan is a drug of particular interest
or use in allogeneic HSCT for IMF patients. The
ombination of busulfan administered at myeloabla-
ive doses (16 mg/kg orally) and cyclophosphamide
as been shown to be superior to total body irradia-
ion and cyclophosphamide in a HSCT study of pa-
ients with Ph-negative MPDs [50]. In addition, the
ombination of ﬂudarabine and reduced-intensity
usulfan (10 mg/kg orally) has produced very prom-
sing results and limited toxicity [56]. Recent studies
ave suggested that intravenous (IV) busulfan limits
he toxicity of this drug [58] and that the combination
f ﬂudarabine and full-dose IV busulfan (12.8 mg/kg
r 130 mg/m2) does not result in major organ toxicity,
uch as veno-occlusive disease [59,60]. Moreover, we
ave recently demonstrated that a ﬂudarabine/mel-
halan RIC regimen and a regimen with ﬂudarabine
nd myeloablative doses of IV busulfan (12.8 mg/kg)
esulted in comparable limited hematologic and extra-
ematologic toxicity [61]. Consequently, we hypoth-
size that both of these regimens may be very effective
n IMF and should be tested in prospective studies.
ue to the lack of large studies of RIC allogeneic
SCT in IMF patients with prolonged follow-up, at
his time it is not yet clear whether the use of agents
apable of in-vivo T-cell modulation/depletion, such
s ATG or alemtuzumab, is beneﬁcial.
A critical issue is the selection of appropriate IMF
atients to undergo allotransplantation. Because pa-
Regimens in Allogeneic HSCT for Myeloﬁbrosis
.) Regimen TRM CR OS
14% (>45 years)
Myeloablative 27% 40% 62% (<45 years) at 5 years
Myeloablative 48% 33% 41% 2.9 years*
Myeloablative 32% 53% 64% 2.8 years*
RIC 10% 76% 86% 2.7 years*
RIC 16% 75% 84% 2.2 years*or RIC
idiate/
-Risk
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R. Hoffman et al.70ients with low-risk disease have a mean survival  10
ears, at this time we do not recommend that these
atients receive allogeneic HSCT from related or un-
elated donors due to the lack of long-term results
ith any type of conditioning regimen. The prognos-
ic implications of such factors as constitutional symp-
oms, hepatomegaly, or absolute number of platelets
42], as well as a possible correlation between disease-
peciﬁc biomarkers, such as high levels of circulating
D34 cells, and/or molecular abnormalities, such as
AK2V617F mutation or MPLW515L, and the clin-
cal outcome, also might contribute to the develop-
ent of more optimal tools to identify IMF patients
ho might beneﬁt from allogeneic HSCT.
The role of splenectomy in IMF before allogeneic
SCT [62,63] remains uncertain. In fact, the high
urgery-related morbidity and mortality (up to 9%),
r the increased risk of leukemic transformation [64],
ould prevent a number of patients from undergoing
n allogeneic HSCT with a potential curative effect.
n the other hand, an extensively enlarged spleen that
ight not be rapidly reduced in size after receiving the
onditioning regimen might limit donor stem cell
ngraftment due to cell sequestration and prolong the
equirement for transfusions after transplantation. An
arlier retrospective analysis of IMF patients who re-
eived myeloablative HSCT found no signiﬁcant dif-
erence in OS or EFS between patients who had or
ad not undergone splenectomy [65]. Future studies
ased on an intent-to-treat analysis are needed to
etter establish the role of splenectomy before alloge-
eic HSCT.
The use of PBSC and RIC regimens in IMF is
eing adopted in many centers with encouraging re-
ults. The development of chronic graft-versus-host
isease in most of these patients [40], although bene-
cial for the long-term control or treatment of a
inimal residual disease, is a potential cause of long-
erm morbidity and mortality.
Recently, new response criteria for evaluating
herapeutic interventions in IMF patients have been
reated. These include clinical, hematologic (eg,
ransfusion independence with improvement/normal-
zation of blood counts and reduction/disappearance
f splenomegaly), and histological parameters (reduc-
ion/disappearance of marrow ﬁbrosis) [66,67]. These
riteria may be very important in analyzing future
linical trials and will facilitate stratiﬁcation of patients
ho achieve a hematologic response after allogeneic
SCT.
DDENDUM
While this manuscript was in press a new study
as published [68] where 9 patients (median age: 54
ears) with myeloﬁbrosis received a RIC prior to al-ogeneic HLA-matched stem cell transplantation from
nrelated (n  7) or related (n  2) donors. The rates
f acute GVHD grade II-IV and II-IV were high
77% and 44%), and this could be partially due to the
se of cyclosporine and mycophenolate as GVHD
rophylaxis in 5/9 patients. In addition, T cell deplet-
ng/immunomudulating agents, such as ATG or ale-
tuzumab, were not used in this study but in one
atient who was re-transplanted after failing to engraft
bone marrow transplant. The elevated incidence of
GVHD also explains, at least in part, a high trans-
lant-related mortality (44%), which has not been
eported in other studies [40,56] using RIC HSCT for
yeloﬁbrosis patients.
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